Participating Companies

Amarin Corporation [AMRN] $540 MM MCap
Com­mer­cial­iz­ing Vas­ce­pa, the first and on­ly pure EPA ome­ga-3 fat­ty acid ap­proved to low­er trig­lyc­eride lev­els in adults. Pre­sent­ed (+) da­ta from RE­DUCE-IT CV Out­comes trial at AHA. First 9mo rev’s of 2020 ~$450M. [more in­for­ma­tion]
Arbor Biotechnologies
An ear­ly-stage life sci­ences com­pany pi­oneer­ing the next-gen­er­a­tion of ge­net­ic medicines. With the most ex­ten­sive li­brary of CRIS­PR nu­cleas­es in the in­dus­try, a deep bench of world-class foun­ders (in­clud­ing gene edit­ing pi­oneer Feng Zhang) and sci­en­tif­ic ad­vi­sors, and a lead­er­ship team with a proven track re­cord of de­vel­op­ing nov­el plat­forms and ther­a­peu­tics, Ar­bor is well-po­si­tioned to de­vel­op cu­ra­tive ge­net­ic medicines for all pa­tients with ge­net­ic dis­eas­es. [more in­for­ma­tion]
Biohaven Pharmaceuticals, Inc [BHVN] $10,159 MM MCap
Com­mer­cial-stage, fo­cused on neu­ro­log­i­cal & neu­ropsychi­a­tric dis­eas­es; CGRP re­cep­tor an­ta­g­on­ist, glu­ta­mate mo­d­u­la­tion, and MPO plat­forms. NURTEC® ODT ap­proved 1Q20 acute treat­ment of mi­graine and 1Q21 pre­ven­tive treat­ment of mi­graine; $136m 3Q21 rev­enues. [more in­for­ma­tion]
Clerio Vision, Inc.
Nov­el oph­thalmic tech­nol­o­gy to treat re­frac­tive er­ror ad­dress­ing mul­ti-bil­lion mar­kets in con­tact lens­es (pres­by­opia, astig­ma­tism, my­opia, my­opia pro­gres­sion) and corneal vi­sion cor­rec­tion (non sur­g­i­cal fla­p­less las­er so­lu­tion). Om­ni­fo­cal con­tact lens pres­by­opia 510k sub­mis­sion and my­opia pro­gres­sion clin­i­cal da­ta in 2H2022. Based on No­bel Prize win­n­ing fem­to-se­cond las­er tech­nol­o­gy de­vel­oped by Bausch & Lomb and the Uni­ver­si­ty of Roch­ester. [more in­for­ma­tion]
ESSA Pharma Inc. [EPIX] $167 MM MCap
Fo­cused on de­vel­op­ing nov­el ther­a­pies for the treat­ment of pros­tate can­cer. ES­SA’s lead clin­i­cal can­di­date, EPI-7386 is an in­vesti­ga­tio­n­al, high­ly-se­lec­tive, oral, small molecule in­hibi­tor of the N-ter­mi­nal do­main of the an­dro­gen re­cep­tor, with Ph 1 monother­a­py da­ta ex­pect­ed in 1H 2022. The com­pany has al­so estab­lished clin­i­cal col­lab­o­ra­tions with JNJ, Astel­las, and Bay­er. [more in­for­ma­tion]
Landos Biopharma [LABP] $25 MM MCap
Pipe­line tar­gets nov­el im­munometabolic path­ways, in­clud­ing LAN­CL2, NL­RX1 and PLXD­C2. Lead as­set omi­lan­cor is a nov­el, oral, gut-re­strict­ed small molecule ther­a­peu­tic can­di­date for the treat­ment of ul­cer­a­tive coli­tis (com­plet­ed Ph2), Crohn’s dis­ease (Ph2) and Eosinophil­ic Esophagi­tis that tar­gets the LAN­CL2 path­way [more in­for­ma­tion]
Marker Therapeutics [MRKR] $27 MM MCap
Fo­cused on de­vel­op­ing next-gen­er­a­tion T cell-based im­munother­a­pies for the treat­ment of he­ma­to­log­i­cal ma­lig­nan­cies and solid tu­mor in­di­ca­tions. Mark­er's cell ther­a­py tech­nol­o­gy is based on the se­lec­tive ex­pan­sion of non-en­gi­neered, tu­mor-spe­cif­ic T cells that rec­og­nize tu­mor as­so­ci­at­ed anti­gens and kill tu­mor cells ex­press­ing those tar­gets. [more in­for­ma­tion]
Minerva Biotechnologies
im­munother­a­pies for can­cer and cel­lu­lar ther­a­pies in re­gen­er­a­tive medicine. First-in-hu­man trial of huM­NC2-CAR44, a CAR T ther­a­py tar­get­ing MUC1* in me­tastat­ic breast can­cers in pa­tients with MUC1* re­ac­tive tu­mors. IND for 1XX ver­sion of this CAR T, which great­ly in­creas­es per­sis­tence and recog­ni­tion of low anti­gen den­si­ty cells will be filed in 2021. [more in­for­ma­tion]
Monte Rosa Therapeutics [GLUE] $363 MM MCap
Next-gen­er­a­tion molec­u­lar glue-based tar­get­ed pro­tein degra­da­tion plat­form de­vel­op­ing small molecule ther­a­peu­tics that se­lec­tive­ly de­grade dis­ease-caus­ing pro­teins. Tar­get­ing the un­drug­gable pro­teome in on­col­o­gy and non-on­col­o­gy in­di­ca­tions via AI based de­gron pre­dic­tion. Lead pro­gram fo­cused on GSP­T1, a key reg­u­la­tor and vul­n­er­a­bil­i­ty of Myc-in­duced trans­la­tio­n­al ad­dic­tion. [more in­for­ma­tion]
Neoleukin Therapeutics [NLTX] $42 MM MCap
Its lead prod­uct can­di­date, NL-201, is a com­bined IL-2 and IL-15 ag­on­ist de­signed to im­prove tol­er­a­bil­i­ty and ac­tiv­i­ty by elim­i­nat­ing the al­pha re­cep­tor bind­ing in­ter­face. NL-201 is cur­rent­ly be­ing eval­u­at­ed in a Phase 1 clin­i­cal trial in pa­tients with re­lapsed or re­frac­to­ry can­cer and the com­pany is ex­pect­ing in­ter­im da­ta in 2022. [more in­for­ma­tion]
Photocure ASA [PHO:OS] NKr2,804 MM MCap
Rev­enue-gen­er­at­ing urol­o­gy-fo­cused com­pany. Lead prod­uct, Hexvix®/Cysview® im­proves de­tec­tion of blad­der can­cer un­der blue light cys­tos­copy (BLC), which can re­duce dis­ease re­cur­rence and pro­gres­sion rates. Hexvix®/Cysview® is in­clud­ed in clin­i­cal consen­sus guide­lines and re­mains on a strong growth path. Rev­enues in 2020 to­taled $31M. Re­cent­ly suc­cess­ful­ly launched the Eu­ro­pean Hexvix op­er­a­tions, con­soli­dat­ing the Com­pany’s prod­uct franchise glob­al­ly. [more in­for­ma­tion]
Ryvu Therapeutics [RVU:WAR]
De­vel­op­er of tar­get­ed on­col­o­gy ther­a­pies in­clud­ing he­ma­tol­o­gy/solid tu­mors. RVU120 is whol­ly-owned first-in-class oral CD­K8/19 in­hibi­tor in Phase I for AML/MDS Small molecule, syn­thet­ic lethal­i­ty plat­form in pre-clin­i­cal de­vel­op­ment in­clud­ing nov­el tar­gets WRN and PRMT5. [more in­for­ma­tion]
Treos Bio Limited
De­vel­ops pre­ci­sion pep­tide can­cer im­munother­a­pies us­ing pa­tient HLA tar­get recog­ni­tion ge­net­ics based on pro­pri­e­tary com­pu­ta­tio­n­al da­ta sci­ence. Tre­os’ lead can­di­date is Po­lyPEPI-1018, an off-the-shelf im­munother­a­py for the treat­ment of me­tastat­ic col­orec­tal can­cer cur­rent­ly in a bio­mark­er-based Phase 1b clin­i­cal trial. Tre­os has raised $42 mil­lion to date. [more in­for­ma­tion]
Vaccitech Plc [VACC] $157 MM MCap
Pro­pri­e­tary ChA­dOx (prime) and MVA (boost) tech­nol­o­gy plat­form in­duces CD8+ T cell and anti­body im­mune re­spons­es to treat and pre­vent in­fec­tious dis­eas­es and can­cer. Broad ther­a­peu­tic pipe­line. En­cour­ag­ing Ph1/2 in­ter­im ef­fi­ca­cy da­ta for VTP-300 (HBV func­tio­n­al cure) and VTP-200 (high-risk HPV ther­a­peu­tic) ef­fi­ca­cy da­ta ex­pect­ed 4Q2022. $15M roy­al­ty rev­enue dur­ing Q42021 from As­traZene­ca's com­mer­cial sales of Vaxzevria® (out-li­censed ChA­dOx COVID-19 vaccine) [more in­for­ma­tion]
Werewolf Therapeutics [HOWL] $124 MM MCap
Were­wolf Ther­a­peu­tics, Inc. is an in­no­va­tive bio­phar­ma­ceu­ti­cal com­pany pi­oneer­ing the de­vel­op­ment of ther­a­peu­tics en­gi­neered to sti­m­u­late the body’s im­mune sys­tem for the treat­ment of can­cer. [more in­for­ma­tion]